Combined Deep Learning Algorithms Demonstrate That Both Computed Tomography Phenotype and Anatomical Biomarkers Are Predictive of Prognosis and Progression in Idiopathic Pulmonary Fibrosis
ATS Journals
Qureight has major presence at 2025 ERS Congress to highlight how advanced imaging biomarkers and AI are transforming interstitial lung disease research and drug development
Appointment of Professor Tamera Corte to Qureight's Scientific Advisory Committee.
Qureight appoints Craig Rhodes as Head of Partnerships to lead on pharma relationship management
Qureight’s AI 3D imaging platform to support Calluna Pharma’s Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF)
Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion
Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment
The Potential for Deep Learning Technology in Clinical Trials
Journal of Clinical Studies
Deep Learning Quantitative Computed Tomography Analysis in the Australian Idiopathic Pulmonary Fibrosis Registry
ATS Journals
Deep Learning-based Disease Severity Biomarkers on CT; Posthoc Analysis in a Phase 2a Placebo-controlled Study of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis
ATS Journals
Monte Carlo External Control Arm Generation Utilising Real-world Patient Data and Deep Learning-based Quantitative CT Metrics Demonstrates Treatment Effect in the Atlas IPF Trial
ATS Journals
Deep Learning-Based Short-Term Disease Progression Evaluation Supersedes Automated Baseline CT Phenotype in Predicting Outcomes in Idiopathic Pulmonary Fibrosis
ATS Journals
Deep Learning-Based Quantitative CT and CT Phenotype Classification Independently Predict Mortality in Idiopathic Pulmonary Fibrosis, a Prospective Observational Cohort Study
ATS Journals
Deep Learning-based Quantitative CT and Proteomics for Predicting Outcomes in Idiopathic Pulmonary Fibrosis
ATS Journals
Dose-Dependent Change of Inhaled Pirfenidone Seen in Lung Volume and Fibrosis Quantification in Patients With IPF: A Deep Learning Image-Based Analysis of Data From the ATLAS Phase 1b Trial
ATS Journals
Qureight partners With Cumberland Pharmaceuticals to advance innovative Idiopathic Pulmonary Fibrosis treatment research
Rein Therapeutics and Qureight broaden life science collaboration
Business Weekly
